EP Patent

EP2545905A1 — A new therapeutical composition containing apomorphine as active ingredient

Assigned to Britannia Pharmaceuticals Ltd · Expires 2013-01-16 · 13y expired

What this patent protects

The present invention relates to a pharmaceutical composition containing apomorphine as the active pharmaceutical ingredient, and more particularly a pharmaceutical formulation for parenteral administration, having a co-solvent, an anti-oxidant and a pH of greater than 4.

USPTO Abstract

The present invention relates to a pharmaceutical composition containing apomorphine as the active pharmaceutical ingredient, and more particularly a pharmaceutical formulation for parenteral administration, having a co-solvent, an anti-oxidant and a pH of greater than 4.

Drugs covered by this patent

Patent Metadata

Patent number
EP2545905A1
Jurisdiction
EP
Classification
Expires
2013-01-16
Drug substance claim
No
Drug product claim
No
Assignee
Britannia Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.